Global Reach of a Turkish Innovation
VenaBlock® is developed and manufactured by INVAMED, a Turkish medical device company specializing in vascular intervention technologies. Since receiving CE marking, VenaBlock® has been adopted in vascular surgery and interventional radiology practices across Europe, Asia, and international markets — a testament to its robust clinical evidence base and physician-friendly design.
Early Adoption: The Singapore Experience
Singapore was among the first centers outside Europe to adopt VenaBlock® at scale, leading to the landmark RIVIERA trial — the first prospective, single-center registry evaluating the system in an Asian patient population. Published in Phlebology, the trial demonstrated high technical success and safety, establishing confidence in VenaBlock® across the Asia-Pacific region.
Subsequent adoption across Singapore, Malaysia, and Indonesia followed, with Indonesian distributor data confirming real-world outcomes consistent with European registry results.
European Clinical Experience
In Europe, VenaBlock® has been adopted at vein centers in Germany, the Netherlands, Italy, Turkey, and several other countries. Its CE marking covers the full intended use — endovenous closure of incompetent superficial truncal veins — and its competitive profile versus VenaSeal™ (a Medtronic product) has made it particularly attractive in cost-sensitive healthcare systems.
Training and Proctoring
INVAMED provides structured physician training programs for VenaBlock®, including hands-on workshops, live case proctoring, and educational resources. The learning curve for experienced phlebologists is short — typically 10–15 supervised cases are sufficient to achieve proficiency, comparable to other catheter-based venous procedures.
Real-World vs. Trial Outcomes
Post-marketing surveillance data from multiple centers confirms that real-world outcomes with VenaBlock® are consistent with clinical trial results. The 93.75% 12-month closure rate observed in controlled registry settings is replicated in routine clinical practice, validating the system's reproducibility in the hands of trained operators across different healthcare settings.